Close Menu

NEW YORK (360Dx) – Bio-Techne this week announced that the US Food and Drug Administration has granted Breakthrough Device designation for its ExoDx Prostate IntelliScore (EPI) test. The FDA designation validates the clinical importance of the EPI test and is intended to accelerate the regulatory review process, Bio-Techne said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.